AEterna Zentaris (AEterna Zentaris) Total Stockholders Equity : $18.20 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris Total Stockholders Equity?

AEterna Zentaris's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $18.20 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. AEterna Zentaris's Book Value per Share for the quarter that ended in Dec. 2023 was $3.75. The ratio of a company's debt over equity can be used to measure how leveraged this company is. AEterna Zentaris's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.02.

AEterna Zentaris Total Stockholders Equity Historical Data

The historical data trend for AEterna Zentaris's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Total Stockholders Equity Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

-2.46

13.21

52.99

35.78

18.20

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial															35.78	31.21	29.08	26.28	18.20

AEterna Zentaris (NAS:AEZS) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

AEterna Zentaris's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(18.196	-	0)	/	4.85588
	=	3.75

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

AEterna Zentaris's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.16	+	0.119)	/	18.196
	=	0.02

AEterna Zentaris Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (AEterna Zentaris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

ET8:Germany ET8:Germany AEZS:Canada

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.